Tandem Diabetes Care (TNDM) Cash from Investing Activities (2016 - 2026)
Tandem Diabetes Care filings provide 13 years of Cash from Investing Activities readings, the most recent being -$15.0 million for Q4 2025.
- On a quarterly basis, Cash from Investing Activities fell 398.92% to -$15.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $72.9 million, a 410.35% increase, with the full-year FY2025 number at $72.9 million, up 410.35% from a year prior.
- Cash from Investing Activities hit -$15.0 million in Q4 2025 for Tandem Diabetes Care, down from $20.5 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $58.1 million in Q2 2025 to a low of -$76.8 million in Q4 2021.
- Median Cash from Investing Activities over the past 5 years was -$5.6 million (2021), compared with a mean of -$9.5 million.
- Biggest five-year swings in Cash from Investing Activities: tumbled 606.62% in 2023 and later skyrocketed 1742.09% in 2025.
- Tandem Diabetes Care's Cash from Investing Activities stood at -$76.8 million in 2021, then surged by 146.57% to $35.8 million in 2022, then tumbled by 146.35% to -$16.6 million in 2023, then skyrocketed by 130.21% to $5.0 million in 2024, then crashed by 398.92% to -$15.0 million in 2025.
- The last three reported values for Cash from Investing Activities were -$15.0 million (Q4 2025), $20.5 million (Q3 2025), and $58.1 million (Q2 2025) per Business Quant data.